Correction to: The Difference in Clinical Outcomes Between Osimertinib and Afatinib for First-Line Treatment in Patients with Advanced and Recurrent EGFR-Mutant Non-Small Cell Lung Cancer in Taiwan.

Details

Language :

English

ISSN :

1776-260X

Volume :

18

Issue :

1

Database :

MEDLINE

Journal :

Targeted oncology

Accession number :

36334173

Full Text :

https://doi.org/10.1007/s11523-022-00928-4